Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
AACR Meeting Highlights
Vice President Biden Promises to Remove Political Barriers to Research, Calls for Cooperation
By
Wayne Kuznar
AACR Meeting Highlights
May 2016, Vol 7, No 4
The realignment of incentives and enhanced collaboration in cancer research are priorities that would speed the pace of discovery, with the goal to “end cancer as we know,” said Vice President Joe Biden at the 2016 American Association for Cancer Research annual meeting. Mr Biden discussed aspects of the new “Moonshot” initiative to eliminate cancer, which was initiated by President Obama at his 2016 State of the Union Address.
Read Article
Nivolumab a New Standard-of-Care Option for Recurrent/Metastatic Head and Neck Cancers
AACR Meeting Highlights
May 2016, Vol 7, No 4
Anti–PD-1 treatment with the PD-1 inhibitor nivolumab (Opdivo) significantly improved survival in patients with head and neck squamous-cell carcinoma that progressed after platinum-based therapy, according to data from a phase 3 clinical trial known as CheckMate-141.
Read Article
New Hope for Patients with Advanced Lung Cancer?
By
Phoebe Starr
AACR Meeting Highlights
May 2015, Vol 6, No 4
Philadelphia, PA—Immunotherapy with pembrolizumab (Keytruda) was safe and effective in the treatment of patients with previously treated as well as treatment-naïve patients with advanced non–small-cell lung cancer (NSCLC), according to results of the KEYNOTE-001 trial, said Edward B. Garon, MD, Assistant Professor of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Santa Monica, who presented these data at the 2015 American Association for Cancer Research (AACR) meeting.
Read Article
Olaparib-Carboplatin Combination Shows Promise for Patients with Ovarian or Triple-Negative Breast Cancer
By
Dana Taylor
AACR Meeting Highlights
May 2015, Vol 6, No 4
Philadelphia, PA—The use of the poly (ADP-ribose) polymerase (PARP) inhibitor, olaparib (Lynparza), plus carboplatin chemotherapy shows promising activity in patients with recurrent breast or ovarian cancer; furthermore, the order of administration of these therapies did not affect the occurrence of side effects, according to new data from a phase 1 clinical trial presented at the 2015 American Association for Cancer Research (AACR) meeting.
Read Article
Metformin May Not Improve Survival in Patients with Pancreatic Cancer
By
Christine Erickson
AACR Meeting Highlights
May 2015, Vol 6, No 4
Philadelphia, PA—Several retrospective studies have shown that metformin is associated with longer survival in patients with cancer, including pancreatic cancer. However, in a new study led by Roongruedee Chaiteerakij, MD, PhD, Division of Gastroenterology and Hepatology, Mayo Clinic Cancer Center, Rochester, MN, metformin did not improve survival for patients with pancreatic ductal adenocarcinoma (PDAC). The results were presented at the 2015 American Association for Cancer Research meeting.
Read Article
Projections for 2030: Increase in ER-Positive, Decrease in ER-Negative Breast Cancer
By
Phoebe Starr
AACR Meeting Highlights
May 2015, Vol 6, No 4
Philadelphia, PA—Over the next 15 years, up to a 50% increase is projected in the number of breast cancer cases, according to a study from the National Cancer Institute (NCI). The incidence of estrogen receptor (ER)-positive breast cancers, diagnosed mostly by mammography, is projected to increase, whereas cases of ER-negative cancers, the more-difficult-to-treat cancers, are projected to decrease. ER-positive in situ cancers are expected to increase by approximately 50% and ER-negative cancers are expected to decrease by approximately 50% by 2030.
Read Article
Liquid Biopsy Detects KRAS Mutations in Plasma DNA in Nonresectable Pancreatic Cancer, Can Predict Patient Outcomes
By
Phoebe Starr
AACR Meeting Highlights
May 2015, Vol 6, No 4
Philadelphia, PA—High levels of KRAS mutations in plasma circulating tumor DNA (ctDNA) predict worse overall survival (OS), whereas low levels of KRAS mutations in plasma ctDNA indicate improved OS in patients with advanced pancreatic cancer.
Read Article
Two Immunotherapies Are Better Than One in Advanced Melanoma
By
Phoebe Starr
AACR Meeting Highlights
May 2015, Vol 6, No 4
Philadelphia, PA—Combination immunotherapy with ipilimumab (Yervoy) plus nivolumab (Opdivo) was superior to ipilimumab monotherapy in previously untreated patients with advanced melanoma in a phase 2 randomized clinical trial, according to lead investigator F. Stephen Hodi, MD, Director of the Melanoma Center, Dana-Farber Cancer Institute, Boston, MA, who presented the study at the 2015 American Association for Cancer Research (AACR) annual meeting.
Read Article
Pembrolizumab Scores Big Over Ipilimumab in Advanced Melanoma
By
Phoebe Starr
AACR Meeting Highlights
May 2015, Vol 6, No 4
Philadelphia, PA—As new immunotherapies become available for the treatment of melanoma and other cancers, head-to-head trials of these agents shed more light on how best to use them. In the phase 3 KEYNOTE-006 trial, pembrolizumab (Keytruda) outperformed ipilimumab (Yervoy)—a current standard of care—as upfront treatment for patients with unresectable advanced melanoma. The data were presented at the 2015 American Association for Cancer Research annual meeting.
Read Article
Page 2 of 2
1
2
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma